Steroids

Matches 301 - 350 out of 894	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
JP7384903B2	fulvestrant prodrug The present invention relates to fulvestrant prodrugs of formula II and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of fulvestrant prodrugs and method of treatment using the same.
JP7339677B2	Fluorosulfonyl-containing compounds, intermediates, methods of preparation and uses thereof Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a c...
JP2023036004A	SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN To provide a salt that can produce a resist pattern having excellent CD uniformity (CDU) and a resist composition comprising the same.The present invention provides a salt represented by formula (I), an acid generator and a resist compos...
JP2023022187A	COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS To provide compositions and methods for treating CNS disorders.Described herein are neuroactive steroids of the formula (II) in the figure or pharmaceutically acceptable salts thereof. Such compounds are supposed, in certain embodiments,...
JP2023503898A	fulvestrant prodrug Invention Name: Prodrug of Fulvestrant The present invention relates to fulvestrant prodrugs and processes for their preparation. The present disclosure also relates to pharmaceutical compositions of fulvestrant prodrugs and methods of t...
JP7190966B2	Salt, acid generator, resist composition and method for producing resist pattern To provide a salt, an acid generator and a resist composition that make it possible to produce a resist pattern with excellent CD uniformity.The present invention provides a salt represented by formula (I), an acid generator and a resist...
JP2022533069A	Small molecule modulator of gut bacterial bile acid metabolism Described herein are methods and compositions for the inhibition of bile salt hydrolases (BSH), as well as their use. Provided herein are metabolic disorders (eg, diabetes, obesity), gastrointestinal disorders (eg, gastrointestinal infec...
JP7077165B2	Method for producing sulfate ester compound To provide a method for producing a sulfate of a hydroxy compound capable of easily producing a sulfate without using special reagents, equipment or reaction conditions and suppressing the decomposition of the hydroxy compound compared w...
JP2022522670A	How to prepare a fulvestrant derivative A method for preparing fulvestrant 3-boronic acid, which comprises converting a compound of formula (IV) to a compound of formula (III), and an intermediate useful for preparing fulvestrant 3-boronic acid by the method are described. .. ...
JP7021080B2	Farnesoid X Receptor Modulator The present application provides a compound of formula I:or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and - - - are as described herein. The present invention relates generally...
JP6984626B2	Resist material and pattern forming method A resist composition comprising a base polymer and an onium salt of N-carbonylsulfonamide having iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU, independent of whether it is of positive or negative tone.
JP6972255B2	Preparations, manufacturing methods and uses of hydrophobic therapeutic agents The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...
JP2021138713A	NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN-3β-25-DIOL DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS To provide a compound for the prevention and treatment of lipid metabolic disorders and inflammatory disorders e.g. hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis.The present disclosure provides 5-cholesten,-3β, 25-d...
JP6893173B2	Compositions and Methods for Treating CNS Disorders Described herein are neuroactive steroids of the Formula (II):or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6and------are as defined herein. Such compounds are envisioned, in certain emb...
JP2021080299A	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES To provide new receptor specific ligand conjugated iRNA agents and methods for their preparation that address shortcomings of in vivo delivery of oligonucleotide therapeutics.The present invention provides iRNA agents comprising at least...
JP2021512909A	Steroidal derivative modulator, its manufacturing method and application The present invention relates to a steroidal derivative modulator, a method for producing the same, and an application thereof. The present invention particularly relates to a compound represented by the general formula (I), a method for...
JP6800748B2	Lipid-based platinum compounds and nanoparticles The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corres...
JP2020180161A	19-NOR NEUROACTIVE STEROIDS AND USE METHODS THEREOF To provide 19-nor neuroactive steroids and use methods thereof.The invention is based, in part, on the desire to provide novel 19-nor (i.e., C19 desmethyl) compounds, e.g., related to progesterone, deoxycorticosterone, and their metaboli...
JP6752940B2	Preparation of hydrophobic therapeutic agents, manufacturing methods and their use The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...
JP6725501B2	Boron-based prodrug strategies for increased bioavailability and lower required doses for drug molecules containing at least one phenol (or aromatic hydroxyl) group Boron-based prodrugs of phenol- or aromatic hydroxyl group -containing therapeutic molecules ("original drugs"), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged r...
JP2020514339A	Catalytic CX-binding metathesis through arylation The present invention relates to a method for catalytic aryl transfer to translocate the scaffold of an aromatic CX bond.
JP6646633B2	Photoacid generator and photoresist containing it New methods are provided for synthesis of photoacid generator compounds ("PAGs"), new photoacid generator compounds and photoresist compositions that comprise such PAG compounds. In a particular aspect, sulfonium-containing (S+) photoaci...
JP6636031B2	Therapeutic compounds and their use and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and meth...
JP6621217B2	Compounds and their use to improve muscle quality Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using ...
JP2019210297A	FARNESOID X RECEPTOR MODULATORS To provide farnesoid X receptor modulators.The present application provides a compound of a formula I in the figure or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof, as described herein. The present inventio...
JP2019529481A	Crystalline morphology of bile acid derivatives The crystal form of the bile acid compound and its preparation and usage are described.
JP6564891B2	Preparation of hydrophobic therapeutic agents, manufacturing methods and their use The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...
JP2019089777A	NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN-3β,25-DIOL DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS To provide a compound for prevention and treatment of lipid metabolic disorders, inflammatory disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis.The compound is 5-cholesten-3,25-diol disulfate (25HCDS) represen...
JP2019511486A	Prodrug (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-diene-3 of selective progesterone receptor modulator (SPRM) -on The present invention relates to prodrug forms of selective progesterone receptor modulators (SPRMs) and their application in treatment. (3α, 11β, 17β) -11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-diene-3,17-dio...
JP6437636B2	Amphiphilic compounds with neuroprotective properties The present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for tr...
JP2018528230A	Methods and intermediates for the preparation of bile acid derivatives Dual agonists targeting both FXR and TGR5 may be useful in the treatment of various liver and metabolic disorders, as well as renal and gastrointestinal disorders. The present invention relates to methods and novel intermediates useful i...
JP6366696B2	S- [4- (3-Fluoro-3-methylbutyryloxy) porcine-2-inyl] 6α, 9α-difluoro-17α- (furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3 -Oxoandrosta-1,4-diene-17β-Method of treating inflammatory conditions using carbothioate The present invention relates to methods of treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy)-but-2-ynyl]6α,9α-difluo ro-17α-(furan-2-yl)carbonyloxy-11β-hydroxy-16α-methyl-3-o xoandrosta-1,4-diene-17β-ca...
JP6285419B2	Preparation of hydrophobic therapeutic agents, manufacturing methods and their use The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...
JP2018503667A	S- [4- (3-Fluoro-3-methylbutyryloxy) Buta-2-inyl] 6α, 9α-difluoro-17α- (furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3 Crystal form of -oxoandrosta-1,4-diene-17β-carbothioate The present invention is S- [4- (3-fluoro-3-methylbutyryloxy) buta-2-inyl] 6α, 9α-difluoro-, which is an anti-inflammatory compound and an anti-allergic glucocorticoid compound. Regarding the crystal morphology of 17α- (furan-2-yl) ca...
JP6272888B2	The process for preparing a bile acid derivative or a pharmaceutically acceptable salt or solvate thereof.
JP2017535570A	Bile acid analogs as FXR / TGR5 agonists and how to use them The present invention relates to compounds of formula (IA) and formula (IB) for treating TGR5-mediated diseases or conditions and pharmaceutically acceptable salts thereof (in formula, R).1, R2, R3, R4, R5, R6, R7, R8, R9And m are as def...
JP2017160213A	NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN-3β,25-DIOL DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS To provide compounds for the prevention and treatment of lipid metabolic disorders and inflammatory diseases, e.g., hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis.The invention provides compounds being 5-cholesten-3,2...
JP6125610B2	A new cholesterol metabolism thing for medical treatment of a metabolic defect, hyperlipemia, diabetes, fatty liver disease, and an atherosclerotic cardiovascular disease, 5-cholesten 3 beta, 25- Diol disulfate (25HCDS) 5-cholesten-3, 25-diol, disulfate (25HCDS) has been found to be an authentic PPAR ³ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflamma...
JP5990557B2	The Andros wardrobe Steroids which has the potential allosteric modulation characteristic of a GABA receptor chloride ionophore, and pregnane steroid This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and...
JP2016505038A	A novel compound of 11β-hydroxysteroids for use in mitochondrial biosynthesis and diseases associated with mitochondrial dysfunction or deficiency The present invention is a novel compound and composition of 11β-hydroxysteroids, as well as pharmaceuticals for preventing or reversing mitochondrial damage in human or animal subjects, for treating or preventing diseases associated wi...
JP5808830B2	Crystal manufacturing method A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowi...
JP2014528485A	3,3-Disubstituted 19-norpregnane compound and its use The 3,3-disubstituted 19-nor-steroid compounds according to formulas (I) and (III) are provided herein: R1, R2, R3, R3', R4, R6a, R6a in the formulas. , R11a and R11b are as defined herein. The compounds of the present invention are inte...
JP5417562B2	17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadiendione as antiprogesterone agents The invention provides 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents.
JP5274453B2	17α-acetoxy-11β- [4- (N, N-dimethyl-amino) -phenyl] -19-norpregna-4,9-diene-3,20-a new intermediate of industrial processes and processes for the synthesis of diones body A new industrial process for the synthesis of solvate-free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpreg na-4,9-diene-3,20-dione [CDB-2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. Th...
JP5230450B2	17-Phosphorus steroid derivative useful as a progesterone receptor modulator The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.
JP5222846B2	Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugate...
JP5199667B2	Methods for the preparation of 17-O-vinyl-triflate as an intermediate A compound of formula (I): or a pharmaceutically-acceptable salt thereof, may be made by a process including a triflating step by which a ketone of formula (II) is converted into a triflate of formula (III): in the presence of a base com...
JP5191079B2	Steroids Sulfatase Inhibitors and Thioethers as Anticancer Compounds-Sulfamate Steroids There is provided a compound of Formula I wherein X is a ring system; R 1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R 2 is any one of a sulphamate group, a...
JP5150607B2	6α, 9α-difluoro-17α-[(2-furanylcarboxyl) oxy] -11β-hydroxy-16α-methyl-3-oxo-androsto-1,4-diene-17-thiocarboxylic acid S as anti-inflammatory agent -Fluoromethyl ester According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
JP5133937B2	7-Procedures and intermediates for the production of substituted antiestrogens A process for preparing an intermediate compound of formula (II) where X is as defined in the specification, R 1 is haloalkyl, alkyl, alkenyl, cycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl or arylalkyl; R 2 , R 3 , R 4 and R 5 are ...

Matches 301 - 350 out of 894	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >